Immuneering Corp
IMRX· Nasdaq
Released Mar 6, 2026, before the open
10-K filed Mar 6, 2026, 65 days after period end · 0001790340-26-000042
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | — | $0.00 | $455.00 |
| Net Income | -$11.58M |
Immuneering Corp · CIK 1790340 · Engraved from SEC EDGAR
| -$18.05M |
| -$15.08M |
| -$13.25M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.